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Background: Multiresistant Gram-negative bacteria producing extended-spectrum β-lactamases (ESBLs) are an
emerging problem in human and veterinary medicine. This study focused on comparative molecular characterization
of β-lactamase and ESBL-producing Enterobacteriaceae isolates from central Hesse in Germany. Isolates originated from
humans, companion animals (dogs and cats) and horses.
Results: In this study 153 (83.6%) of the human isolates (n = 183) and 163 (91.6%) of the animal isolates (n = 178) were
confirmed as ESBL producers by PCR and subsequent sequencing of the PCR amplicons. Predominant ESBL subtypes in
human and animal samples were CTX-M-15 (49.3%) and CTX-M-1 (25.8%) respectively. Subtype blaCTX-M-2 was found
almost exclusively in equine and was absent from human isolates. The carbapenemase OXA-48 was detected in 19
ertapenem-resistant companion animal isolates in this study. The Plasmid-encoded quinolone resistance (PMQR)
gene aac(‘6)-Ib-cr was the most frequently detected antibiotic- resistance gene present in 27.9% of the human and
36.9% of the animal ciprofloxacin-resistant isolates. Combinations of two or up to six different resistance genes
(penicillinases, ESBLs and PMQR) were detected in 70% of all isolates investigated. The most frequent species in
this study was Escherichia coli (74%), followed by Klebsiella pneumoniae (17.5%), and Enterobacter cloacae (4.2%).
Investigation of Escherichia coli phylogenetic groups revealed underrepresentation of group B2 within the animal
isolates.
Conclusions: Isolates from human, companion animals and horses shared several characteristics regarding
presence of ESBL, PMQR and combination of different resistance genes. The results indicate active transmission
and dissemination of multi-resistant Enterobacteriaceae among human and animal populations.
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Extended-spectrum beta-lactamase (ESBL)-producing En-
terobacteriaceae are isolated with increasing frequency
from human and animal samples. In particular, the species
Escherichia (E.) coli plays an important role as a source of
the corresponding resistance genes [1]. ESBLs genes are
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article, unless otherwise stated.by conjugation to other bacteria, even across species
barriers. In addition, various resistance genes are lo-
cated in or close to mobile genetic elements such as in-
sertion sequences and transposons [2]. Lateral gene
transfer and continuous DNA recombination make it
extremely difficult to track transmission pathways of
ESBL genes in bacterial populations. The transmission
of ESBL-producing pathogens or ESBL genes between
companion animals/livestock and owner/caretaker/con-
sumer is currently a subject of intense and controversial
discussion. Evidence has been presented for zoonotictral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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infection that could arise from keeping animals [5-7]. A
recent study highlighted that the risk factors for ESBL
carriage were travel to Greece or Africa within the last
12 months and keeping of pet animals, but not anti-
biotic consumption or recent hospitalization [8]. Until
now, it is still difficult to estimate the amount of ex-
change and even more difficult to define the risk for hu-
man and animal health and also food safety.
The focus of this study was a comparative investigation
of 361 ESBL-producing Enterobacteriaceae isolates ob-
tained from animals and human patients presenting at a
veterinary clinic and a hospital, respectively, both serving
a similar catchment area. The prevalence of β-lactamase-,
particularly ESBL-producing bacteria in companion ani-
mal, horse and human isolates of clinical origin was exam-
ined. Resistance genes (β-lactamase and plasmid-mediated
quinolone resistance (PMQR)) and E. coli phylogenetic
groups were investigated using molecular methods.
This work sheds light on shared populations of ESBL-
producing Enterobacteriaceae in symptomatic companion
animals, horses and humans in the geographical region of
middle Hesse, Germany.Methods
Bacterial isolates
A collection of 513 Enterobacteriaceae isolates resistant to
one or more third-generation cephalosporins (200 human
isolates and 313 animal isolates) was examined. Identifica-
tion was done using in-house biochemical tests. In case of
ambiguous results confirmation was done using API 20E.
Prior to further analysis, all isolates were grown on Mac-
Conkey agar supplemented with cefotaxime (2 mg/l) to
promote selection of β-lactamase producers and ensure
selection of Enterobacteriaceae. Afterwards isolates were
tested for possible ESBL production by double disc syn-
ergy test (DDST) according to EUCAST guidelines for re-
sistance mechanisms [9]. After performance of the DDST
183 human and 178 animal isolates were categorized as
possible ESBL-producers and forwarded for a more de-
tailed investigation. Isolates with a negative DDST result
were not included in the study.
DDST-positive isolates from human clinical samples
(n = 183) were taken from the strain collection of the In-
stitute of Medical Microbiology, Giessen. Some of the
isolates originate from routine screening for colonization
with ESBL-producing Enterobacteriaceae at the University
hospital Giessen. Additional isolates were collected from
samples of clinically ill patients e.g. blood culture or urine
samples in the same facility. All isolates were collected be-
tween 2009 and 2010. Approximately two-thirds of the
human isolates originated from inpatients (n = 128) and
one third were isolates from outpatients wards (n = 55).DDST-positive isolates from animals (n = 178) were
obtained during a survey for aerobic Gram-negative bac-
teria growing on MacConkey agar supplemented with
cefotaxime (2 mg/l) among animal patients at the veter-
inary clinics of the Justus Liebig University (JLU) Giessen.
All samples were clinically relevant infection related iso-
lates. The isolates originated from horses (n = 100), dogs
(n = 67) and cats (n = 11) and were collected between
2009 and 2011.
The study was approved by the ethics committee of
medical faculty of the Justus Liebig University of Giessen
and deemed exempt from informed consent.
Antibiotic susceptibility
Antibiotic susceptibility testing was done using the
VITEK®2 compact system with AST N117 cards (Bio-
mérieux) and Etest® stripes (Liofilchem®) containing erta-
penem, cefepime, chloramphenicol and nalidixic acid.
Results were evaluated according to CLSI guidelines for
human pathogens (CLSI, 2012).
β-lactamase identification
For antibiotic resistance genes screening by PCR and iden-
tification by sequencing were performed as described pre-
viously [10]. Specific oligonucleotide primers for blaTEM,
blaSHV [11], blaCTX-M genes [12] and blaOXA-1 [13] were
used. The MAST carbapenemase detection set (MAST
group, UK) was applied on carbapenem-resistant iso-
lates. Furthermore, primers for blaOXA-48 were used for
carbapenem-resistant isolates [11]. With the exception
of blaOXA-1-positive strains, amplicons of PCR-positive
strains were sequenced to identify the encoded ESBL al-
lele in detail. Sequencing was performed using the auto-
mated sequencer ABI Prism® 3100 (Life technologies,
USA). The blastn algorithm of NCBI (http://www.ncbi.
nlm.nih.gov/blast/) was used for database searches to
identify the resistance gene allele. The primers and the
sequences they were derived from are presented in
Table 1. Positive control strains from the Institute of
Microbiology, Giessen, Germany, were Klebsiella (K.)
pneumoniae H59 for blaTEM, blaSHV, blaCTX-M, blaOXA-1
and aac(6’)-Ib, Klebsiella pneumoniae 714 for blaOXA-48.
For the qnr-genes, strains from the Institute of Hygiene
and Infectious Diseases of Animals, Giessen, Germany
(V148 for qnrA, V167 for qnrB, V60 for qnrD and V61 for
qnrS), were used as positive controls after sequencing and
comparison with known sequences using DNASTAR soft-
ware (DNASTAR Inc, Madison, USA) and the NCBI
blastn algorithm.
Detection of Plasmid-encoded quinolone resistance
(PMQR)
Detection for PMQR by PCR was performed on all iso-
lates with a minimum inhibitory concentration (MIC) ≥
Table 1 PCR primers used to detect β-lactamase genes, PMQR genes and E. coli phylogenetic groups
Primer Sequence (5’ - 3’) Target Size of product (bp) Reference
TEM_f ATGAGTATTCAACATTTCCG blaTEM 851 [11]
TEM_r TTAATCAGTGAGGCACCTAT
SHV_f GCAAAACGCCGGGTTATTC blaSHV 940 [11]
SHV_r GGTTAGCGTTGCCAGTGCT
CTX-M_f TCTTCCAGAATAAGGAATCCC blaCTX-M 909 [12]
CTX-M_r CCGTTTCCGCTATTACAAAC
OXA-1_f AGCAGCGCCAGTGCATCA blaOXA-1 700 [13]
OXA-1_r ATTCGACCCCAAGTTTCC
OXA-48_f AAATCACAGGGCGTAGTTGTG blaOXA-48 555 [11]
OXA-48_r GACCCACCAGCCAATCTTAG
qnrA_f AGAGGATTTCTCACGCCAGG qnrA 619 [14]
qnrA_r GCAGCACTATKACTCCCAAGG
qnrB_f GGMATHGAAATTCGCCACTG qnrB 264 [16]
qnrB_r TTTGCYGYYCGCCAGTCGAA
qnrC_f GGGTTGTACATTTATTGAATC qnrC 447 [17]
qnrC_r TCCACTTTACGAGGTTCT
qnrD_f CGAGATCAATTTACGGGGAATA qnrD 582 [18]
qnrD_r AACAAGCTGAAGCGCCTG
qnrS_f GCAAGTTCATTGAACAGGCT qnrS 428 [16]
qnrS_r TCTAAACCGTCGAGTTCGGCG
qepA_f CTGCAGGTACTGCGTCATG qepA 403 [15]
qepA_r CGTGTTGCTGGAGTTCTTC
aac_f TTGCGATGCTCTATGAGTGGCTA aac(6’)-Ib 482 [19]
aac_r CTCGAATGCCTGGCGTGTTT
chuA.1 GACGAACCAACGGTCAGGAT chuA 279 [21]
chuA.2 TGCCGCCAGTACCAAAGACA
YjaA.1 TGAAGTGTCAGGAGACGCTG yajA 211 [21]
YjaA.2 ATGGAGAATGCGTTCCTCAAC
TspE4C2.1 GAGTAATGTCGGGGCATTCA TspE4C2 152 [21]
TspE4C2.2 CGCGCCAACAAAGTATTACG
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isolates: n = 122). Oligonucleotide primers for detection of
qnrA, qnrB, qnrC, qnrD, qnrS, qepA and aac(6’)-Ib were
used [14-19]. Identification of the aac(6’)-Ib-cr variant was
performed according to Jones et al. 2008 [20].
Phylogenetic groups of ESBL-producers
Distribution of E. coli phylogenetic groups was analysed
by PCR targeting genes chuA, yjaA and the DNA frag-
ment TSPE4.C2 to assign the strains to the groups A,
B1, B2 and D according to Clermont et al. 2000 [21].
Analysis of resistance genes patterns
Information regarding the source of isolates, species
and the resistance genes detected were assembled intoan Excel file. The data was subsequently analysed using
GENE-E [22] which enables the clustering of data with
matrix visualization and analysis to support visual data
exploration.
Results
Overview of bacterial species
The majority of the isolates studied were E. coli (74%),
followed by K. pneumoniae (17.5%) and Enterobacter
cloacae (4.2%). Other species detected were Klebsiella
oxytoca, Enterobacter intermedius, Citrobacter freundii,
Providencia stuartii, Morganella morganii and Proteus
mirabilis. The percentages of E. coli and K. pneumoniae
isolates among the human and animal isolates were very
similar.
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All isolates (n = 361) were categorised as multidrug resist-
ant (MDR) according to the international expert proposal
for interim standard definitions for acquired resistance
promoted by the ECDC [23]. Both human (n = 183) and
animal isolates (n = 178) revealed resistance against ampi-
cillin and trimethoprim/sulfmethoxazole. Slight differences
could be observed concerning the tested third generation
cephalosporins ceftazidime, cefotaxime and cefepime. Of
the human isolates 52.5% (n = 96) showed resistance
against ceftazidime, 78.7% (n = 144) resistance against cefo-
taxime and 98.4% (n = 180) resistance against cefepime. Of
the animal isolates 75.8% (n = 135) displayed resistance
against ceftazidime and 99.4% (n = 177) to cefotaxime and
cefepime. Of the human isolates 2.2% (n = 4), and 1.1%
(n = 2) of the animal isolates revealed resistance against
imipenem. Resistance against the other tested carbapenem
(ertapenem) was detected in 24.5% (n = 45) of human iso-
lates and in 19.7% (n = 35) of animal isolates. The amino-
glycosides gentamicin and amikacin differed in their results.Table 2 Distribution of β-lactamase genes in Enterobacteriace
Source Human
Outpatients Inpatients D
No. of isolatesa 55 128
Penicillinasesb
blaTEM-1 58.2 (32) 41.4 (53) 62
blaTEM-190 1
blaSHV-1 2.3 (3) 16
blaSHV-11 1.6 (2)
blaOXA-1 23.6 (13) 32.8 (42) 59
ESBLb
blaTEM-52 2.3 (3)
blaSHV-2 1
blaSHV-5 0.8 (1)
blaSHV-28
blaCTX-M-1 32.7 (18) 45.3 (24) 16
blaCTX-M-2
blaCTX-M-9
blaCTX-M-14 1
blaCTX-M-15 54.5 (30) 51.6 (66) 59
blaCTX-M-32 1.8 (1) 0.8 (1)
blaCTX-M-38 0.8 (1)
blaCTX-M-79 1.8 (1) 2.3 (3)
blaCTX-M-97 1.8 (1)
blaCTX-M-117 0.8 (1)
Carbapenemasesb
blaOXA-48 23
anumerous isolates encoded for more than one β-lactamase gene.
b% of β-lactamase genes (no. of isolates).Only 5.1% (n = 9) of animal isolates exhibited resistance
against amikacin, as compared to 14.8% (n = 27) of the hu-
man isolates. The resistance rates against gentamicin were
higher in both cases with 35% (n = 64) in human isolates
and 62.4% (n = 111) in animal isolates. High resistance rates
in both groups were also revealed for the fluoroquinolone
ciprofloxacin (76.5% (n = 140) of the human isolates and
68.5% (n = 122) of the animal isolates).
Distribution of β-lactamases
Almost all isolates carried at least one beta-lactamase
(bla)-gene (Table 2). In all, 91.6% of the animal isolates
and 83.6% of the human isolates were confirmed as
ESBL producers by PCR and sequencing. The remaining
isolates (7.5%) were negative for the presence of blaTEM,
blaSHV, blaOXA-1, blaOXA-48 and blaCTX-M.
CTX-M
Subtypes of the ESBL CTX-M were by far the most fre-
quently encoded ESBLs in both groups (Table 2 andae isolates (n = 361) of human and animal origin
Animal
ogs Cats Horses Total no. of isolates
67 11 100 361
.7 (42) 45.5 (5) 67 (67) 55.1 (199)
.5 (1) 0.3 (1)
.4 (11) 2 (2) 4.4 (16)
0.6 (2)
.7 (40) 45.5 (5) 29 (29) 35.7 (129)
0.8 (3)
.5 (1) 9.1 (1) 0.6 (2)
0.3 (1)
3(2) 1(1) 0.8 (3)
.4 (11) 27.3 (3) 37 (37) 25.8 (93)
9.1 (1) 15 (15) 4.4 (16)
3 (2) 9.1 (1) 1 (1) 1.1 (4)
.5 (1) 0.3 (1)
.7 (40) 36.4 (4) 38 (38) 49.3 (178)
0.6 (2)
0.3 (1)
1(1) 1.4 (5)
3(3) 1.1 (4)
0.3 (1)
.9 (16) 18.2 (2) 1(1) 5.3 (19)
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CTX-M-1 and 52.5% CTX-M-15. Some human isolates
carried blaCTX-M-79, blaCTX-M-32, blaCTX-M-97, blaCTX-M-38
or blaCTX-M-117. The blaCTX-M-1 gene was found in
32.7% of human outpatient isolates and in 45.3% of in-
patient isolates, while prevalence rates of blaCTX-M-15
were high and similar in both groups (outpatients 54.5%,
inpatients 51.6%). Animal isolates revealed similar results
as 28.7% of these isolates carried blaCTX-M-1 and 46.1%
blaCTX-M-15. Other detected blaCTX-M genes were
blaCTX-M-2, blaCTX-M-9, blaCTX-M-97, blaCTX-M-79, and
blaCTX-M-14. The presence of blaCTX-M-2, blaCTX-M-9,
and blaCTX-M-14 was restricted to animal isolates, while
blaCTX-M-32, blaCTX-M-38, blaCTX-M-117 were found only
among the human isolates. BlaCTX-M-1 was the domin-
ant resistance subtype in horses (37%) but it was less
frequently isolated in dogs (16.4%). In contrast, blaCTX-M-15
occurred more often in dog isolates (59.7%) than in isolates
from horses (38%) or cats (36.4%). In addition, blaCTX-M-15
was also the dominant CTX-M subtype among K. pneu-
moniae isolates whereas among the E. coli isolates both
subtypes were present to the same degree. Altogether,
blaCTX-M-1 and blaCTX-M-15 were the prominent β-
lactamase genes present in 25.8% and 49.3% of all investi-
gated isolates.
TEM
Non-ESBL gene blaTEM-1 was the most frequently iden-
tified β-lactamase gene among all investigated isolates. It
was detected in 46.4% of the human isolates and in 64%
of all animal isolates. It was present in 199 of 361 iso-
lates (55%). The highest detection rates were observed in
outpatients (58.2%), inpatients (41.4%), dog isolates
(62.7%) and horse isolates (67%). TEM-52 was the only
TEM-type ESBL that occurred in this study. It was iden-
tified in three isolates from human inpatients. Results
are shown in Table 2.
SHV
Prevalence of blaSHV was 17.2% in human and 52.9% in
animal K. pneumoniae. BlaSHV-1 was identified in 10.3%
of the human and in 29.4% of the animal K. pneumoniae
isolates. Several ESBL variants could be identified in
addition (Table 2). Most of the latter isolates originated
from dogs. Detected SHV-type ESBL genes were blaSHV-2,
blaSHV-5, blaSHV-11 and blaSHV-28. BlaSHV-5 and blaSHV-11
were restricted to isolates from human inpatients. ESBL
genes blaSHV-2 and blaSHV-28 were detected among the
animal isolates only.
OXA-1
The presence of the penicillinase gene blaOXA-1 could be
demonstrated in 30.1% of the human isolates. Among
the animal isolates blaOXA-1 was identified in 41.6% ofall strains. Detection rates were highest in isolates from
dogs (59.7%), followed by cat (45.5%), outpatient (32.8%)
and horse (29%) isolates. However, blaOXA-1 was also
found in inpatient isolates (23.6%) (Table 2).
OXA-48
All carbapenem resistant isolates (human isolates: 45,
animal isolates: 40) were tested for presence of the car-
bapenemase OXA-48. None of the tested human isolates
harboured blaOXA-48. In contrast, 19 (5.3%) of the animal
isolates harboured this gene. The isolates harbouring
blaOXA-48 originated from dogs (16), cats (2) and a horse
(Table 2).
PMQR
Distribution and presence of PMQR genes are illustrated
in Table 3. The most frequently detected PMQR gene in
ciprofloxacin-resistant isolates (n = 262) was aac(‘6)-Ib-
cr. Prevalence was 27.9% (n = 39) in the human isolates,
36.9% (n = 45) in the animal isolates and 32.1% (n = 84)
in all investigated isolates. None of the isolates carried
qnrC or qepA. Among the human isolates qnrB was
found in three and qnrS in five isolates. Two more qnr
variants were detected among the animal isolates. Gene
qnrA was carried by three, qnrB by seven, qnrD by eight
and qnrS by five animal isolates. Most qnr type genes
(qnrA, qnrB, qnrD, qnrS) were detected in dog isolates.
Inpatient isolates carried PMQR genes at higher rates
(37.8%) than isolates from outpatients (23.8%). A similar
observation could be made among the animal isolates.
Highest identification rates (49.5%) were observed in iso-
lates originating from animals tested during stay in the
small animal clinic. In summary, most PMQR genes
were present in dog isolates (65.1%). Overall, PMQR
genes could be demonstrated in 43.9% (n = 115) of all in-
vestigated isolates.
Analysis of resistance gene patterns
Preliminary detection and visualization of clusters and/
or resistance patterns in context to isolate source and
bacterial species was performed using Figure 1 which
was generated by means of the GENE-E program. Data
was then confirmed by analysis of absolute and relative
numbers/ percentages as displayed in Table 4. Combina-
tions of various plasmid encoded resistance genes (ESBL
and non-ESBL β-lactamases and PMQR) were observed
in the majority of isolates (70.1%) included in this study
(Table 4 and Figure 1). Most frequently detected (26.3%)
was the combination of a TEM type penicillinase with a
CTX-M type ESBL. Also regularly observed was a peni-
cillinase (TEM or OXA-1) in combination with CTX-M
and plasmid-mediated quinolone resistance (PMQR)
genes. These combinations were predominantly found
among E. coli isolates. Other isolates encoded for
(n = 53)
(n = 110)
not present
species (n = 27)
(n = 60)
15
1
60)
genes
Outpatients
Dogs (n = 62)
Inpatients
Horse (n = 98)
Cats (n = 11)
Species/resistance gene 
Other bacterial
K. pneumoniae 
CTX-M-
CTX-M-
E. coli (n = 
Other resistance
A B
Figure 1 Heat maps generated from identified resistance genes and bacterial species among human and animal isolates. Identified
resistance genes and bacterial species are listed according to frequency (except for CTX-M-1 and CTX-M-15) on the right and left side of the
figures. Source = origin of isolates (outpatients, inpatients, dogs, cats, horses). Not included are isolates without detectable resistance gene
(n = 28). The term “Other species” includes Enterobacter cloacae (n = 12), Klebsiella oxytoca (n = 9), Enterobacter intermedius (n = 2), Enterobacter
gergoviae (n = 1), Citrobacter freundii (n = 1) and Proteus mirabilis (n = 1). A is focussing on the origin of isolates whereas the B emphasizes the
involved bacterial species.
Schmiedel et al. BMC Microbiology 2014, 14:187 Page 6 of 13
http://www.biomedcentral.com/1471-2180/14/187
Table 3 Distribution of PMQR genes in ciprofloxacin-resistant isolates (n = 262) of human and animal origin
% of PMQR genes (no. of isolates)
Source No. of isolatesb qnrA qnrB qnrC qnrD qnrS qepA aac(6’)-Ib-cr
Human
Outpatients 42 4.8 (2) 19 (8)
Inpatients 98 3.1 (3) 3.1 (3) 31.6 (31)
Total 140 2.1 (3) 3.6 (5) 27.9 (39)
Animal
Dogs 63 1.6 (1) 7.9 (5) 4.8 (3) 1.6 (1) 49.2 (31)
Cats 10 20 (2) 20 (2) 40 (4)
Horses 49 10.2 (5) 8.2 (4) 20.4 (10)
Total 122 2.5 (3) 5.7 (7) 6.6 (8) 4.1 (5) 36.9 (45)
Total no. of isolates 262 1.1 (3) 3.8 (10) 3.1 (8) 3.8 (10) 32.1 (84)
bsome isolates encoded for more than one PMQR gene.
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enzymes, the penicillinase blaOXA-1, the penicillinase
blaSHV and PMQR genes. The carbapenemase OXA-48
was mainly associated with numerous resistance genes
such as a TEM penicillinase, CTX-M and PMQR. In
addition, it was exclusively identified in K. pneumoniae
and Enterobacter cloacae isolates from animals. Another
frequently observed combination was that of blaCTX-M-
15 and aac(‘6)-Ib-cr. Other combinations were detected
only once or to a much lesser extent than those men-
tioned above. Combination of more than two resistance
genes could be observed more often among human E.
coli isolates and especially among K. pneumoniae animal
isolates (Figure 1).
Phylogenetic grouping of β-lactamase-producing E. coli
Phylogenetic group typing was applied to 141 human
and 126 animal ESBL-producing E. coli isolates (Table 5
and Figure 2). Both groups differed from each other in
the frequencies of known phylogenetic groups. In gen-
eral, the human isolates were almost evenly distributed
among the phylogenetic groups A (30.5%), B1 (27.7%)
and B2 (26.2%) and to a lesser extent with group D
(15.6%). In contrast, most of the analysed animal isolates
belonged to group A (43.7%) and a considerably smaller
number of isolates to B1 (35.7%). Approximately 17.5%
of all animal isolates could be assigned to group D,
whereas only 2.4% were classified as group B2.
Discussion
The global spread of multi-resistant ESBL-producing En-
terobacteriaceae can in part be explained by mobility of
the resistance bearing genetic elements e.g. plasmids,
transposons and insertion sequence elements. This fact
is a major concern in terms of epidemiology and infec-
tion control. Transmission pathways between humans
and animals are currently a subject of active discussion[8,24,25]. This study was designed to investigate the distri-
bution of β-lactamases, particularly ESBL, and PMQR
genes among isolates from human, companion animal and
horse samples in a defined geographical area of Germany.
The key question was whether similar resistance charac-
teristics are currently present among both groups. Indeed,
our studies here demonstrate that isolates from human
and animal samples share numerous characteristics.
Antimicrobial susceptibility testing revealed common
and disturbing patterns. High resistance rates for all β-
lactams and other antibiotic classes were observed. In
particular animal isolates harbouring resistance to the
last-resort antibiotics ertapenem and impenem were de-
tected. The results for ertapenem were particularly alarm-
ing, with 16.3% resistance among animal isolates and 24%
among the human isolates. In Germany, the use of carba-
penems in livestock animals is prohibited and its use for
treating companion animals is strongly restricted. Never-
theless, almost all ertapenem resistant strains among the
animal isolates (95.6%) originated from dogs and cats.
This would suggest human to animal transmission of re-
sistant strains by their owners. Alternatively, the use of
carbapenems for treatment of companion animals cannot
be excluded even though these pharmaceuticals are ex-
pensive and their use is uncommon even in pet animal
practice. Carbapenemase activity in bacteria from com-
panion animals and livestock has been already identified
recently [26-28]. To investigate this phenomenon in more
detail, all carbapenem resistant isolates from this study
were tested for the presence of blaOXA-48. Surprisingly, a
substantial difference could be observed regarding the
molecular mechanisms underlying this resistance pheno-
type. None of the 45 tested human isolates was positive
for blaOXA-48, though 26 (57.8%) were identified with a
possible combination of an AmpC enzyme and porin defi-
ciency. This mechanism has been observed previously in
AmpC-producing K. pneumoniae by Shi et al. They stated
Table 4 Observed combinations of β-lactamase and PMQR genes according to bacterial species
Combination of
resistance genesa
Outpatients Inpatients Dogs Cats Horses
% of bacterial species (no. of isolates)
EC KP KO EN OSb EC KP KO EN OSb EC KP KO EN OSb EC KP KO EN OSb EC KP KO EN OSb
TEMPen/CTX-M 50 (24) 26.9 (25) 12 (3) 17.1 (6) 20 (1) 40.7 (35) 25 (1)
TEMPen/CTX-M/
PMQR
25 (1) 1.2 (1) 25 (1) 2.9 (1) 20 (1) 33.3 (1) 8.1 (7)
TEMPen/CTX-M/
OXAPen
2.1 (1) 33.3 (1) 2.2 (2) 14.3 (5) 12.8 (11) 10 (1)
TEMPen/CTX-M/
OXAPen/PMQR
4.2 (2) 25 (1) 8.6 (8) 8 (2) 8.6 (3) 18.2 (4) 100 (1) 12.5 (1) 20 (1) 1.2 (1) 40 (4)
TEMPen/SHVPen/
CTX-M/OXAPen/
PMQR
4 (1) 9.1 (2) 20 (2)
TEMPen/SHVPen/
CTX-M/OXAPen/
OXACarba/PMQR
22.7 (5)
TEMPen/CTX-M/
OXAPen/OXACarba/
PMQR
27.3 (6) 50 (1)
CTX-M/OXAPen/
PMQR
8.3 (4) 14 (13) 12 (3) 17.1 (6) 20 (1) 3.5 (3)
TEMPen/SHVPen/
OXACarba/PMQR
37.5 (3)
CTX-M/PMQR 2.2 (2) 20 (1) 5.7 (2) 12.5 (1) 33.3 (1)
CTX-M/OXAPen 8.3 (4) 6.5 (6) 8 (2) 2.9 (1) 20 (1) 8.1 (7)
Other
combinations
2.1 (1) 25 (1) 3.2 (3) 16 (4) 22.7 (5) 12.5 (1) 50 (1) 33.3 (1) 20 (2)
No resistance
gene detected
4.2 (2) 14 (13) 12 (3) 50 (2) 8.6 (3) 12.5 (1) 100 (1) 2.3 (2)
Single resistance
gene
20.8 (10) 25 (1) 66.7 (2) 21.5 (20) 28 (7) 80 (4) 25 (1) 100 (1) 22.9 (8) 12.5 (1) 20 (1) 1 23.3 (20) 10 (1) 75 (3)
Total no. of
isolates
48 4 3 0 0 93 25 5 4 1 35 22 1 8 1 5 2 0 3 1 86 10 0 0 4
EC, Escherichia coli; KP, Klebsiella pneumoniae; KO, Klebsiella oxytoca; EN, Enterobacter cloacae; OS, Other species.
aTEMPen, TEM Penicillinase, OXAPen, OXA Pencillinase, OXACarba, OXA Carbapenemase, SHVPen, SHV Penicillinase.
bOther species include Enterobacter intermedius (n = 2). Enterobacter gergoviae (n = 1), Citrobacter freundii (n = 1), and Proteus mirabilis (n = 1), Providencia stuartii (n = 1), Morganella morganii (n = 1).
Schm
iedelet
al.BM
C
M
icrobiology
2014,14:187
Page
8
of
13
http://w
w
w
.biom
edcentral.com
/1471-2180/14/187
Table 5 Distribution of E. coli phylogenetic groups among human and animal isolates (n = 267)
% of phylogenetic groups (no. of isolates)
Source No. of isolates A B1 B2 D
Human
Outpatients 48 31.3 (15) 29.2 (14) 25 (12) 14.6 (7)
Inpatients 93 30.1 (28) 26.9 (25) 26.9 (25) 16.1 (15)
Total 141 30.5 (43) 27.7 (39) 26.2 (37) 15.6 (22)
Animal
Dogs 35 48.6 (17) 22.9 (8) 2.9 (1) 25.7 (9)
Cats 5 60 (3) 20 (1) 20 (1)
Horses 86 40.7 (35) 41.9 (36) 2.3 (2) 14 (12)
Total 126 43.7 (55) 35.7 (45) 2.4 (3) 17.5 (22)
Total no. of isolates 267 36.7 (98) 31.5 (84) 14.9 (40) 16.5 (44)
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can result in reduced susceptibility to carbapenems [29].
In contrast to these results, 19 (47.5%) of the 40 examined
animal isolates harboured an OXA-48 carbapenemase.
Among 361 isolates resistant to one or more third gen-
eration cephalosporins 84% harboured a CTX-M type en-
zyme. Predominant ESBL genes in human and animal30,50%
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43,70%
35,70%
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Figure 2 Distribution of E. coli phylogenetic groups among human an
human (n = 141) and animal (n = 126) sources were assigned to E. coli phylsamples were blaCTX-M-15 and blaCTX-M-1. In the past
blaCTX-M-15 was merely associated with isolates from
humans [30] and CTX-M-1 was the major CTX-M sub-
type in cattle and pigs in Europe [31]. In addition
blaCTX-M-1 was also detected in companion animal and
poultry isolates [32,33]. In the meantime, attribution of
the above-named CTX-M types as specific to either26,20%
15,60%
3,20%
17,50%
B2 D
groups
Human isolates
Animal isolates
d animal ESBL-producing isolates. A total of 267 isolates from
ogenetic groups A, B1, B2 and D.
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creasing number of studies have identified blaCTX-M-1
and blaCTX-M-15 in both populations [3,34] and our
study confirmed this development. Among our isolates
blaCTX-M-15 was the most prevalent ESBL gene which
occurred in approximately 50% of the strains investi-
gated (human: 52.5%, animal: 46.1%). The number for
blaCTX-M-1 was considerably lesser but this gene was
still relatively frequently present (23%, 28.7%). Isolates
collected from horses seemed to hold a special position
since rates of blaCTX-M-1- and blaCTX-M-15-positive iso-
lates were almost equal (blaCTX-M-1 37%; blaCTX-M-15
38%). Previous studies have mainly identified CTX-M-1
as the predominant ESBL subtype among horse isolates
[35,36], which is also the most common type among
livestock. In Germany horses are mostly used as recre-
ational animals, normally situated close to livestock or
in livestock-like environments. However, they usually
have closer contact to humans and in case of disease
medical care for horses is much more intense than in
agricultural animal species. This could be a possible ex-
planation for the particularly high detection rates of
blaCTX-M-15 reported here. Interestingly, blaCTX-M-2 was
found almost exclusively in equine E. coli isolates and
was not present among human isolates. A study from
Belgium identified blaCTX-M-2 as major CTX-M subtype
among diseased horses [37]. These animals had received
prolonged treatment with several antibiotics and the
blaCTX-M-2 gene was part of the novel complex class 1
integron ISCR1. Ferreira et al. could demonstrate the
same linkage between blaCTX-M-2 and ISCR1 however,
within the chromosome of E. coli isolates from healthy
broiler chickens in Brazil [38]. Further investigation of
the region surrounding the blaCTX-M-2 gene may be neces-
sary to identify possible associations with ISCR1 among
the isolates examined in this work. However, the CTX-M-
2 subtype is not restricted to animal or even horse isolates.
It was previously found in Salmonella enterica isolates
from the UK and E. coli isolates from Brazil originating
from clinically ill human patients [39,40].
Ciprofloxacin-resistant animal isolates (55.7%) showed
higher prevalence of PMQR-encoding genes compared
to human isolates (33.6%). In addition, four qnr-variants
(qnrA, qnrB, qnrD and qnrS) were identified in the group
of animal isolates, compared to only qnrB and qnrS
among the human isolates. All identified qnr variants have
already been identified in both groups, however no study
is consistent with the results found here [41,42].
Another interesting result is the low prevalence of
blaSHV-1 among the K. pneumoniae isolates (10.3% of the
human and in 29.4% of the animal K. pneumoniae iso-
lates). Even though it is widely considered a plasmid-
encoded enzyme, it has been found at high frequencies in
K. pneumoniae. Further the blaSHV-1 origin is suspected inthe chromosome of K. pneumoniae [43]. As some au-
thors indicate high frequencies of up to 90% in K. pneu-
moniae isolates, our data does not seem to fit into the
picture [43]. Yet there are other studies showing also
low prevalences [44]. Based on these data it could be a
local phenomenon.
The β-lactamase genes blaSHV-1, blaSHV-5, blaSHV-11 and
blaTEM-52 were restricted to isolates from inpatients.
This fact could be explained by their ancestry, since
these genes are frequently found in isolates from hospi-
tals [45].
Combination of various resistance genes was the rule
rather than the exception (Table 4). In 70.1% of all iso-
lates two or more genes responsible for β-lactam or
quinolone resistance were identified. Combinations of
several β-lactamase genes are commonly observed regu-
larly within genomes of Gram-negative bacterial patho-
gens [46,47] and co-selection of β-lactamase genes and
determinants for resistance against other antibiotics e.g.
fluoroquinolones has been postulated as a possible mech-
anism responsible for the widespread distribution of those
combined genes [48]. The frequently observed combin-
ation of blaCTX-M-15 and aac(‘6)-Ib-cr could provide gen-
etic support for this theory, which has been noted before
[49,50]. For this study the presence of blaOXA-48 in com-
bination with at least two penicillinase genes e.g. TEM,
SHV or OXA, a PMQR gene and even sometimes with a
CTX-M gene is alarming. Even more worrying is the fact
that almost all isolates identified with the OXA-48 car-
bapenemase originate from companion animals. How-
ever, other carbapenemases could be present among the
human and animal isolates, which were not tested for.
The carbapenem-resistant animal isolates were mainly K.
pneumoniae and Enterobacter cloacae isolates. An unre-
lated study conducted in our geographic region also de-
tected carbapenem-resistant Klebsiella spp. among isolates
from dogs [26].
E. coli and K. pneumoniae are the main species associ-
ated with β-lactamase production among isolates resist-
ant to third generation cephalosporins in Germany and
other members of the European Union [51]. Data from
this study underlines this predominance of both bacter-
ial species as a carrier of ESBL-encoding resistance genes
with 74% E. coli and 17.5%K. pneumoniae isolates in total.
Interestingly, the phylogenetic group B2 was strongly un-
derrepresented among the ESBL-E. coli isolates from
animals. Compared to the human isolates (26.2%) it was
only present in 2.4%. The origins of primary sample ma-
terial could provide an explanation for this discrepancy.
Several studies suggest dominance of certain phylogen-
etic groups in particular specimen and types of infection
[52,53]. Zhang et al. demonstrated clustering of phylo-
genetic group B2 among urinary E. coli isolates from hu-
man patients [52]. The fact that 53% of the human
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while only 19% were from rectal swabs suggests an asso-
ciation between higher numbers of B2-E. coli isolates
and the urinary tract of humans. The main source for
the animal isolates was faeces (51%) from animals suf-
fering from enteritis, diarrhoea and colic. It is not
known whether the ESBL isolates detected were indeed
causative for the syndromes observed as they could also
be commensal strains that were selectively isolated
solely on the basis of their resistance phenotype. This
could explain the strong presence of phylogenetic group
A/B1 and almost complete lack of group B2. Neverthe-
less, the pathogenic potential of ESBL-encoding isolates
remains uncertain and needs further research. Studies
performed on E. coli harbouring β-lactamases revealed
several virulence-associated traits such as toxins, fimbriae,
siderophores, polysaccharide coatings and invasins [54,55].
In addition, patients with bacteremic urinary tract infec-
tions (UTIs) caused by ESBL-producing Enterobacteriaceae
also have prolonged hospitalization and higher antibiotic
costs [56].
Our study has limitations with regard to the selection of
isolates. Human isolates originate from screening of pa-
tients upon admission for carrier-status as well as from
clinically ill patients, whereas animal isolates only derive
from diseased animals. In addition, selection criteria for
ESBL- or PMQR-carrying isolates might have introduced
bias. A screening breakpoint of >1 mg/L is recommended
for cefotaxime in accordance with the guidelines issued by
EUCAST [9]. Usage of the higher concentration of 2 mg/
L might have led to loss of some ESBL types. PMQR-
genes typically induce low-level quinolone-resistance with
ciprofloxacin MIC of ≥ 0.25 μg/mL [57]. For this reason
some PMQR may not have been detected due to the MIC
of 1 μg/mL used.
Notwithstanding, the study gives an overall view on
current dissemination of ESBL-encoding Enterobacteria-
ceae isolates within the region investigated. Further stud-
ies should be directed to examining specific transmission
pathways assessing the exchange between the human and
animal populations in owner-pet studies. In order to ad-
dress this aspect in more detail, simultaneous screening
of pets and/or owners positive for ESBL-producing En-
terobacteriaceae should be carried out in the future. An-
other important factor for possible transmission or spread
is the environment. Multiresistant bacteria are isolated
with increasing frequencies from soil or water and wild-
life [58]. Some studies implicate ESBL-producing E. coli
already as a form of environmental pollution [59]. Our
findings are supported by other non-regional studies
that confirm the data presented [4,60,61]. In line with
this work several studies describe presence of ESBL pro-
ducing Enterobacteriaceae among human and animal
samples with dominance of the CTX-M subtype [1-3].Other aspects such as the colonisation and persistence
in humans, animals and the environment as well as host
species adaption and interspecies transmissibility of the
bacteria involved must be taken into account. As plasmids
are epidemiologically relevant agents in ESBL transfer,
their role and association with sequence types (STs) need
to be examined. Transfer of similar plasmids from human
to animal bacterial populations and vice versa has been
shown in broilers and broiler farmers in the Netherlands
[62] and suggest that a similar situation could also exist
between pet and owner.
Conclusions
The results from this study substantiate the alarming oc-
currence and ongoing spread of various ESBL-producing,
multiresistant Enterobacteriaceae strains in the human and
animal populations within a defined geographic region in
central Hesse, Germany. Our data confirm that companion
animals represent novel reservoirs of carbapenemase-
producing strains of K. pneumoniae and Enterobacter
cloacae. The study strongly supports the One Health
concept which expands interdisciplinary collaborations
and communications in all aspects pertaining to the
health care for humans and animals [63].
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